wbldb
home
|
authors
|
theses
Burnett-Bowie, Sherri-Ann M.
Links
Google Scholar:
skcZ-JwAAAAJ
Affiliations (2)
Name
Count
Oldest
Newest
Massachusetts General Hospital
5
2013
2022
Harvard Medical School
2
2022
2022
Papers (5)
Year
Article
Times Cited
Times Cited (no self-citations)
2015
Tsai JN, Uihlein AV, Burnett-Bowie S-AM, Neer RM, Zhu Y, Derrico N, Lee H, Bouxsein ML, Leder BZ. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study.
J Bone Miner Res
. January 2015;30(1):39-45.
19
17
2022
Johannesdottir F, Putman MS, Burnett-Bowie S-AM, Finkelstein JS, Yu EW, Bouxsein ML. Age-related changes in bone density, microarchitecture, and strength in postmenopausal black and white women: the SWAN longitudinal HR-pQCT study.
J Bone Miner Res
. January 2022;37(1):41-51.
2
2
2022
Karlamangla AS, Shieh A, Greendale GA, Yu EW, Burnett-Bowie S-AM, Sluss PM, Martin D, Morrison A, Finkelstein JS. Anti-mullerian hormone as predictor of future and ongoing bone loss during the menopause transition.
J Bone Miner Res
. July 2022;37(7):1224-1232.
1
1
2013
Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie S-AM, Neer RM, Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Lancet
. July 6, 2013;382(9886):50-56.
25
19
2015
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-AM. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Lancet
. September 19-25, 2015;386(9999):1147.
25
22
Collaborators (3)
Name
Count
Oldest
Newest
Tsai, Joy N.
3
2013
2015
Bouxsein, Mary L.
2
2015
2022
Leder, Benjamin Z.
3
2013
2015